Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.75 | N/A | +16.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.75 | N/A | +16.44% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a positive outlook regarding their earnings performance, particularly on EPS. However, they did not provide any updated guidance for future quarters.
Management expressed satisfaction with the EPS performance.
They highlighted ongoing efforts in research and development.
No specific guidance was provided for future quarters.
Pfizer's strong EPS performance, exceeding expectations, led to a positive stock reaction with a 2.49% increase. The company remains focused on its research and development efforts, which may contribute to future growth. However, the lack of guidance leaves some uncertainty about the upcoming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
T-MOBILE US INC
Oct 28, 2019